AR112354A1 - OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM - Google Patents

OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM

Info

Publication number
AR112354A1
AR112354A1 ARP180101289A AR112354A1 AR 112354 A1 AR112354 A1 AR 112354A1 AR P180101289 A ARP180101289 A AR P180101289A AR 112354 A1 AR112354 A1 AR 112354A1
Authority
AR
Argentina
Prior art keywords
hydrolyzed
obtaining
pharmaceutical compositions
compositions containing
probiotic
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Arjona Valeska Aeschlimann
Margarita Gonzlez
Yez Rodrigo Brquez
Mara Jos Aguayo
Juan Pablo Mellado
Moreno Mara Piderit
Inostroza Erica Castro
Original Assignee
Univ San Sebastian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ San Sebastian filed Critical Univ San Sebastian
Publication of AR112354A1 publication Critical patent/AR112354A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

La solicitud desarrollada en el campo de los productos biotecnológicos naturales, describe un compuesto basado en hidrolizado proteico soluble (HPS) de la cepa probiótica Lactobacillus spp DSM32447. En particular, la solicitud refiere a un compuesto de origen natural, inocuo que confiere inmunidad de mucosas, se describe el método de obtención, composiciones farmacéuticas que lo contienen y uso de las mismas. Reivindicación 1: Un método para producir una composición inmuno estimulante caracterizado porque comprende los pasos: i) centrifugar una suspensión bacteriana de la cepa Lactobacillus spp DSM32447, ii) resuspender el pellet obtenido en ii) en PBS, iii) sonicar el producto de ii), iv) centrifugar el lisado iii), recuperando el sobrenadante, v) deshidratar el sobrenadante, vi) disolver 100 mg de hidrolizado proteico en 5 ml de agua destilada estéril, vii) agregar preservante.The application developed in the field of natural biotechnological products describes a compound based on soluble protein hydrolyzate (HPS) from the probiotic strain Lactobacillus spp DSM32447. In particular, the application refers to a compound of natural origin, innocuous that confers immunity to mucous membranes, the method of obtaining it, pharmaceutical compositions containing it and the use thereof are described. Claim 1: A method to produce an immunostimulating composition characterized in that it comprises the steps: i) centrifuging a bacterial suspension of the strain Lactobacillus spp DSM32447, ii) resuspending the pellet obtained in ii) in PBS, iii) sonicating the product of ii) , iv) centrifuge the lysate iii), recovering the supernatant, v) dehydrate the supernatant, vi) dissolve 100 mg of protein hydrolyzate in 5 ml of sterile distilled water, vii) add preservative.

ARP180101289 2017-05-17 2018-05-16 OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM AR112354A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017001273A CL2017001273A1 (en) 2017-05-17 2017-05-17 Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.

Publications (1)

Publication Number Publication Date
AR112354A1 true AR112354A1 (en) 2019-10-23

Family

ID=63046376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101289 AR112354A1 (en) 2017-05-17 2018-05-16 OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM

Country Status (4)

Country Link
AR (1) AR112354A1 (en)
CL (1) CL2017001273A1 (en)
EC (1) ECSP19088005A (en)
WO (1) WO2018209457A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674826A (en) * 2019-01-31 2019-04-26 吉林省知遇科技有限公司 A kind of probiotic composition for nursing female reproductive system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2087094T3 (en) * 2006-11-17 2014-05-12 Sca Hygiene Prod Ab LACTOBACILLUS FERMENTUM ESS-1, DSM17851 AND ITS APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF CANDIDIASIS AND URINAL INFECTIONS
EP2540818A1 (en) * 2008-09-04 2013-01-02 OM Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
CL2009001511A1 (en) * 2009-07-02 2009-10-23 Univ De Concepcion 61 02% Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.
GB201409541D0 (en) * 2014-05-29 2014-07-16 Univ Manchester Probiotic Bacteria
EP3064072A1 (en) * 2015-02-11 2016-09-07 AB-Biotics S.A. Probiotic lactobacillus strains for use in treating urinary tract infections

Also Published As

Publication number Publication date
WO2018209457A1 (en) 2018-11-22
ECSP19088005A (en) 2020-05-29
CL2017001273A1 (en) 2018-03-16

Similar Documents

Publication Publication Date Title
BR112018077266A2 (en) compositions comprising bacterial strains
MX2018002340A (en) Methods and compositions for immune protection against extra-intestinal pathogenic e. coli.
WO2015052350A3 (en) Live attenuated vaccines
MX2021014983A (en) Oral rehydration composition and methods thereof.
WO2008036675A8 (en) Compositions and methods of enhancing immune responses
BR112019007803A2 (en) glycoconjugate vaccine formulations against expec
WO2007048086A3 (en) Canine influenza virus and related compositions and methods of use
BR112022008533A2 (en) COMPOSITION FOR INCREASE BLOOD BIOAVAILABILITY OF AMINO ACIDS, THEIR USE, FOOD PRODUCT, USE OF A MIXTURE, AND USES OF PROBIOTIC BACTERIAL STRAINS
CO2018009538A2 (en) Use of bacterial strains belonging to the species lactobacillus kefiri in pediatrics to generate and / or maintain a state of homeostasis
BR112017009790A2 (en) anti-ang2 antibodies and methods of use
BR112014015390A2 (en) vesicular stomatitis virus for initial and booster vaccines
MX2019006104A (en) Immunogenic conjugates and use thereof.
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
AR112354A1 (en) OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM
CL2020001975A1 (en) Compositions and methods of use of novel strains of lactobacillus fermentum. (divisional request 201801680)
NZ596501A (en) Casb7439 constructs
WO2012009774A3 (en) Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods
HRP20191864T1 (en) Clostridium difficile immunogenic composition
BR112015019748A2 (en) PEPTIDE HAVING PL AND/OR PLA2 INHIBITORY ACTIVITY, FOOD PRODUCT SUITABLE FOR THE TREATMENT OF OBESITY AND/OR OXIDATIVE STRESS, AND, USE OF STREPTOCOCCUS THERMOPHILUS CNCM I-2776 AND/OR STREPTOCOCCUS THERMOPHILUS CNCM I-1630 AND/OR LACTOBACILLUS PARACASEI SUBSP PARACASEI CNCM I-4270
MY167069A (en) Antigen peptide and use thereof
WO2016056026A3 (en) Synergistic composition for osteoarthritis
MX2019006105A (en) nOMV-ANTIGEN CONJUGATES AND USE THEREOF.
WO2019126341A3 (en) Compositions and methods for the treatment of bacterial infections
MY153741A (en) A method for producing bio-active agent for the prevention of disease caused by white spot syndrome baculovirus complex and a bio-active agent derived thereof
Mufida et al. Peran protein membran luar 55 KDa Salmonella typhi isolat Jember sebagai protein hemaglutinin dan adhesin